Cell and gene therapy (CGT) manufacturers face one of the most complex quality system environments in regulated industry. FDA regulates these products under the biologics framework (21 CFR Parts 210, 211, and 600), the CGTP regulations (21 CFR Part 1271), and, for gene therapy products, CBER-specific guidance. In January 2026, FDA announced a flexible approach to chemistry, manufacturing, and controls (CMC) requirements for CGTs to encourage innovation, but this flexibility comes with expectations for robust, documented quality systems. This guide covers the regulatory framework, the quality system elements FDA expects, and the practical challenges of building a compliant QMS for advanced therapy manufacturing.

Why cell and gene therapy QMS requirements are different

Cell and gene therapies differ from conventional pharmaceuticals in ways that directly affect quality system design. The starting material is often a patient’s own cells (autologous) or donor cells (allogeneic). The manufacturing process transforms living biological material, which means process variability has biological consequences that a tablet press or a reactor making a small molecule cannot produce. Chain of identity, chain of custody, and donor eligibility screening are quality activities with no equivalent in conventional drug manufacturing.

The regulatory framework reflects this complexity. FDA regulates most CGT products under both the biologics framework (which applies manufacturing standards comparable to 21 CFR Part 211) and the CGTP regulations in 21 CFR Part 1271, which address the specific risks of human cell and tissue products. Gene therapy products manufactured using viral vectors are additionally subject to CBER product-specific guidance documents.

In January 2026, FDA announced flexible CMC requirements for cell and gene therapies specifically to reduce development barriers for rare disease products while maintaining safety standards (FDA, 2026). The announcement acknowledged that applying the same rigidity of CMC requirements to one-time advanced therapies as to commercially manufactured blockbuster drugs had slowed development without proportionate safety benefit. Flexibility in CMC, however, does not mean flexibility in quality system requirements. FDA’s inspections of CGT manufacturers continue to apply rigorous quality system standards.

The regulatory framework for CGT quality

21 CFR Part 1271: Current Good Tissue Practice (CGTP)

Part 1271 applies to human cells, tissues, and cellular and tissue-based products (HCT/Ps). It establishes requirements for donor eligibility determination, current good tissue practice, labeling, reporting, and registration. For CGT products that meet the definition of HCT/Ps, CGTP requirements apply in addition to the biologics manufacturing standards.

Key quality system elements under CGTP include: written procedures for all manufacturing steps, a quality program with designated quality oversight, personnel training and qualification, facilities and equipment controls, environmental monitoring, process controls and in-process testing, labeling controls, and records management. These elements parallel the quality system requirements in 21 CFR Part 820 (QMSR) and ISO 13485, but with added biological and donor safety considerations.

21 CFR Parts 210 and 211: cGMP for biological products

Cell and gene therapy products approved as biologics are subject to cGMP requirements comparable to 21 CFR Parts 210 and 211, which govern pharmaceutical manufacturing. This includes validated manufacturing processes, environmental monitoring, calibrated and qualified equipment, batch record requirements, release testing, and stability programs. FDA’s application of these requirements to CGTs is adapted to the unique characteristics of living-cell products, but the core quality system obligations remain.

21 CFR Part 600: Biologics licensing requirements

Part 600 establishes the licensing framework for biological products and includes requirements for facilities, personnel, records, and product testing that apply during the pre-approval phase and continue after commercialization. For CGT manufacturers, the BLA (Biologics License Application) process requires a comprehensive quality system assessment as part of the application.

Core quality system elements for CGT manufacturing

Chain of identity and chain of custody

For autologous cell therapies, the patient whose cells are collected is the same patient who will receive the finished product. A mix-up in chain of identity is a life-threatening adverse event. Quality systems for autologous CGT must include procedures, controls, and verification steps at every stage of manufacturing that confirm the identity of the material being processed. This typically involves barcoded labeling, dual-operator verification at critical identity checkpoints, and automated tracking systems linked to the patient identifier.

Chain of custody documentation must trace the product from donor collection through manufacturing, release, shipping, and administration. FDA inspectors treating CGT manufacturing facilities will ask to walk through chain of identity and custody controls in detail. Gaps in these records are among the most serious CGT quality failures because they suggest that a mix-up may have occurred, even if it did not.

Donor eligibility and screening

Both autologous and allogeneic CGT products require donor eligibility determinations under 21 CFR Part 1271. Allogeneic products require infectious disease testing of the donor to reduce transmission risk to the recipient. The quality system must include SOPs for donor screening, documented results of eligibility testing, a process for handling ineligible donor material, and records that link the eligibility determination to the specific lot manufactured from that donor.

For clinical-stage programs, donor eligibility determinations must be made before manufacturing. For commercial programs, the documentation must be available for FDA review and must be part of the batch record for each lot.

Environmental monitoring and cleanroom controls

CGT manufacturing typically occurs in ISO-classified cleanrooms with strict environmental monitoring programs. Environmental monitoring (EM) includes viable and non-viable particle counts, surface and personnel monitoring, and media fills to demonstrate aseptic technique. The EM program must be qualified, the acceptance criteria must be documented, and exceedances must be investigated through the CAPA system.

FDA’s inspection focus on CGT environmental monitoring is intensifying. CBER inspectors have cited inadequate EM programs and failure to investigate environmental excursions as significant observations in CGT facility inspections. A well-designed EM program with a documented trending process is a quality system differentiator for CGT manufacturers.

Process characterization and validation

CGT manufacturing processes involve multiple biological steps: cell collection, isolation, activation, transduction or transfection, expansion, formulation, and fill/finish. Each step must be characterized to understand its variability and critical parameters. Commercial-stage products require process validation demonstrating that the process consistently produces a product meeting predetermined specifications.

FDA’s flexible CMC approach for rare disease CGTs may reduce pre-approval validation requirements, but post-approval process performance qualification is still expected. Quality systems must include validated cleaning procedures, equipment qualification, and a process performance monitoring program that generates trending data for ongoing commercial manufacturing.

Batch records and material traceability

CGT batch records must document every manufacturing step, every input material, every in-process test result, every environmental monitoring result, and every deviation from procedure that occurred during manufacturing. For autologous products, the batch record is patient-specific. For allogeneic products, the batch record may cover a lot manufactured from one donor across multiple patient doses.

Material traceability requirements in CGT are more demanding than in conventional pharma because the starting material is a defined biological entity (a specific patient’s cells, or a specific donor’s cells) rather than a chemical ingredient whose source can be substituted if one supplier has quality issues. Every raw material used in manufacturing, including culture media, cytokines, and viral vectors, must be traceable from its source through the lot used in each patient’s product.

Release testing

CGT product release testing includes identity testing (confirming the product is what it claims to be), potency testing (confirming it has the intended biological activity), purity testing (absence of process-related impurities and contaminants), safety testing (sterility, mycoplasma, viral adventitious agents), and in some cases dose testing. The release testing program must be validated, the specifications must be set based on clinical and manufacturing experience, and release decisions must be documented in the batch record with approval by a qualified person.

Out-of-specification (OOS) test results in CGT require the same investigation process as in conventional pharma, but the consequences of an OOS result for a time-sensitive autologous product are more acute. A contaminated autologous cell therapy lot may have no replacement, and the patient is often in a clinical condition where delay is medically significant. Quality systems must include procedures for handling OOS results that account for the clinical urgency and the regulatory reporting requirements.

Deviation and CAPA management

Deviations from manufacturing procedures are a routine part of CGT manufacturing, particularly at the clinical stage where processes are still being optimized. The quality system must have a low threshold for deviation reporting, a rapid investigation process, and a mechanism to assess the impact of each deviation on product quality and patient safety. Deviations that affect chain of identity, donor eligibility status, or aseptic conditions require immediate escalation to quality leadership and may require product quarantine.

CAPA management in CGT must address both systemic process problems and one-time procedural failures. An effective CAPA program includes trending of deviation data by category, route cause, and product to identify patterns that require systemic correction.

FDA’s evolving approach to CGT inspections

FDA announced in January 2026 that it was applying a flexible, risk-based approach to CMC oversight for CGTs, particularly for products targeting rare diseases with small patient populations (FDA, 2026). This approach acknowledges that the traditional CMC development paradigm, designed for blockbuster drugs with thousands of development patients, does not fit products where the total clinical population may be fewer than 100 people.

Flexibility in CMC does not mean relaxed quality oversight. FDA’s CBER division continues to conduct pre-approval inspections of CGT manufacturing facilities and post-approval surveillance inspections of commercial facilities. The focus of these inspections includes chain of identity controls, environmental monitoring programs, deviation management, and the adequacy of the quality system to govern a manufacturing process that operates at the edge of biological complexity.

A June 2026 warning letter to Genzyme Ireland related to post-approval CGT manufacturing oversight illustrates that FDA’s expectations for post-approval CGMP compliance remain high, even where pre-approval flexibility was granted (Clinical Trial Vanguard, 2026).

Building a CGT quality system that scales

Most CGT companies design their quality systems for clinical-stage manufacturing and find that the same system does not scale to commercial manufacturing without significant rework. The quality system design decisions made at the IND stage have long-term consequences for BLA readiness and commercial manufacturing scalability.

A robust CGT quality system should be built on an eQMS platform capable of managing the full complexity of advanced therapy manufacturing: batch record traceability, chain of identity workflows, environmental monitoring trending, deviation management, CAPA, change control, and supplier qualification for raw materials including viral vectors. Cloudtheapp’s 60+ quality application platform is configurable to the specific workflows of CGT manufacturing, including patient-specific tracking for autologous products, EM trending, and integrated deviation and CAPA management. Request a demo to discuss how Cloudtheapp can support your CGT quality system from IND to BLA and beyond.

Frequently asked questions

Are cell and gene therapies regulated as drugs or as devices?

Cell and gene therapies are regulated as biological products under the biologics framework, not as devices. CBER (Center for Biologics Evaluation and Research) has primary regulatory authority. Some combination products that include a biological component combined with a device component are reviewed by CBER or CDER depending on the primary mode of action. Gene editing tools delivered via devices may require coordination between CBER and CDRH.

Does 21 CFR Part 820 (QMSR) apply to CGT manufacturers?

21 CFR Part 820 (QMSR) applies to medical device manufacturers. Most cell and gene therapy products are biologics, not devices, so QMSR does not directly apply. However, the quality system principles in QMSR and ISO 13485 are broadly consistent with the quality expectations FDA applies to CGT manufacturers under the biologics framework. CGT companies building their quality systems often find value in using ISO 13485 or QMSR as a structural framework, even where those standards are not technically required.

What is the most common quality system failure FDA finds in CGT facility inspections?

Based on 483 observation patterns and published inspection reports, the most frequent quality system failures in CGT facilities involve environmental monitoring programs (inadequate program design, failure to investigate excursions, missing EM data in batch records), chain of identity controls (gaps in verification documentation), and deviation management (underreporting of deviations, inadequate investigation depth, CAPA actions not addressing systemic root causes).

Conclusion

Cell and gene therapy quality systems must meet the same core quality management standards as any biologics or pharmaceutical manufacturer while addressing unique challenges that conventional drug manufacturing does not encounter. Chain of identity, donor eligibility, environmental monitoring at aseptic manufacturing scale, and process variability management in living cell systems require quality system design that goes beyond adapting a pharmaceutical quality manual. FDA’s 2026 flexibility initiative reduces some pre-approval CMC burdens, but the quality system expectations that govern manufacturing are as rigorous as ever. Companies that build their quality systems for scalability and regulatory defensibility from the outset will have a clearer path from clinical-stage to commercialization than those who defer quality system design until BLA preparation forces the issue.

This post created by and appeared first on Cloudtheapp